Sneak Preview: R&D Investments Must Focus On India’s Competitive Advantages
This article was originally published in The Pink Sheet Daily
Executive Summary
India has unique capabilities for genomic databases, translational research and nanotechnology, which should spur research on cancer leads, according to a BCG report to be released May 11.
You may also be interested in...
Sneak Preview: BCG Study Predicts Strong R&D Focus In India; Big Pharma May Leverage India For "Niche Busters" And Stem Cells
MUMBAI - Research-related investments funnelled into India by U.S.-based pharmaceutical companies swelled by 10 times between 2002 and 2009 to reach $121 million, a number that will continue to grow in the years to come, according to an upcoming study by the Boston Consulting Group. The report, which was commissioned by the USA-India Chamber of Commerce (USAIC), will be released June 23 during the annual USA-India BioPharma & Healthcare Summit in Boston
Launching Clinical Trials In India? Beware Of Long Delays And New Mandates
MUMBAI - Inordinate delays in the approval process for clinical trials may be dissuading sponsors and CROs from considering India as part of their upcoming global programs
Clinical Trials Flood India But Infrastructure Woes Stifle Cancer Trials
AHMEDABAD, India - As the number of clinical trials grow steadily in India to reach over $1 billion in turnover, a peculiar "problem of plenty" faces clinical trials for specialized cancer drugs